Showing results (301-310 of 380) with videos related to
Sort By:
Pageof 38
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2020
Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced MelanomaCaroline Robert, Georgina V Long, Benjamin Brady, et al.JAMA Network Open|June 4, 2025
Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic DisordersKylie Fletcher, Marc Machaalani, Razane El Hajj Chehade, et al.JAMA Oncology|November 14, 2018
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 TrialPaolo A Ascierto, Georgina V Long, Caroline Robert, et al.The New England Journal of Medicine|November 18, 2014
Nivolumab in previously untreated melanoma without BRAF mutationCaroline Robert, Georgina V Long, Benjamin Brady, et al.Journal of Neuro-Oncology|January 9, 2016
Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous systemJohannes van de Nes, Marco Gessi, Antje Sucker, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2022
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant MelanomaMartin Schuler, Lisa Zimmer, Kevin B Kim, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 24, 2025
International survey on training of dermatology residents in supportive oncodermatology: the RESCUE studyAriadna Ortiz-Brugués, Davide Fattore, Marie Boileau, et al.The Lancet. Oncology|March 22, 2015
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trialJeffrey S Weber, Sandra P D'Angelo, David Minor, et al.European Heart Journal|August 14, 2021
Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapyLars Michel, Iris Helfrich, Ulrike Barbara Hendgen-Cotta, et al.Frontiers in Immunology|March 3, 2025
Presence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation statusJan-Malte Placke, Luisa Sophie Rajcsanyi, Rudolf Herbst, et al.Pageof 38